References
- Engels EA, Chatterjee N, Cerhan JR, Davis S, Cozen W, Severson RK, Whitby D, Colt JS, Hartge P. Hepatitis C virus infection and non-Hodgkin lymphoma: Results of the NCI-SEER multicenter case-control study. hit J Cancer 2004;111(1):76–80.
- Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999;17: 3835–3849.
- Ambrosetti A, Zanotti R, Pattaro C, Lenzi L, Chilosi M, Caramaschi P, Arcaini L, Pasini F, Biasi D, Orlandi E, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated wither with Sjoegren syn-drome or hepatitis C virus infection. Br J Haematol 2004;126 (1):43–49.
- Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347(2):89–94.
- Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. Binding of hepatitis C virus to CD81. Science 1998;282: 938–941.
- De Vita S, De Re V, Sansonno D, Sorrentino D, La Corte R, Pivetta B, Gasparotto D, Racanelli V, Marzotto A, Labom-barda A, et al. Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: Viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis. Hepatology 2000;31(1):182–189.
- Tursi A, Brandimarte G, Torello M. Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy. J Chin Gastroenterol 2004;38:360–363.
- De Vita S, Sansonno D, Dolcetti R, Ferraccioli G, Carbone A, Cornacchiulo V, Santini G, Crovatto M, Gloghini A, Dammacco F. A role for hepatitis C virus infection in type II cryoglobulinemia. Blood 1995;86:1887–1892.
- Loustaud-Ratti V, Riche A, Liozon E, Labrousse F, Soria P, Rogez S, Babany G, Delaire L, Denis F, Vidal E. Prevalence and characteristics of Sjögren's syndrome or Sicca syndrome in chronic hepatitis C virus infection: A prospective study. J Rheumatol 2001;28:2245–2251.
- Miklos JA, Swerdlow SH, and Bahler DW. Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobu-lin VH genes show frequent use of V1-69 with distinctive CDR3 features. Blood 2000;95:3878–3883.
- De Re V, De Vita S, Gasparotto D, Marzotto A, Carbone A, Ferraccioli G. Salivary gland B cell lymphoproliferative disorders in Sjogren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkin's lymphomas. Eur J Immunol 2002;32:903–910.
- Hadziyannis SJ, Sate H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, et al. PEGASYS International Study Group. Peginterferon-[alpha]2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140(5):370 — 381.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347: 975 —982.
- Veldt BJ, Saracco G, Boyer N, Cammá C, Bellobuono B, Hopf U, Castillo I, Weiland O, Nevens F, Hansen BE, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004;53:1504–1508.